title: Catecholamines restore myocardial contractility in dilated cardiomyopathy at the expense of increased coronary blood flow and myocardial oxygen consumption (MvO2 cost of catecholamines in heart failure).
abstract: To investigate the metabolic cost of catecholamine use in heart failure, we administered intravenous dobutamine or norepinephrine to dogs with moderate and severe LV dysfunction until LV contractile function was restored to normal levels. Both drugs were associated with significant increases in myocardial O(2) consumption, increased coronary blood flow requirements and decreased myocardial mechanical efficiency. These mechanisms may contribute to the deleterious effects of catecholamines in heart failure.
authors.affiliation: Department of Medicine, Allegheny General Hospital, Drexel University College of Medicine, 320 E. North Avenue, Pittsburgh, PA 15212, USA.
authors.forename: Lazaros A
authors.initials: LA
authors.lastname: Nikolaidis
authors.forename: Dennis
authors.initials: D
authors.lastname: Trumble
authors.forename: Teresa
authors.initials: T
authors.lastname: Hentosz
authors.forename: Aaron
authors.initials: A
authors.lastname: Doverspike
authors.forename: Rhonda
authors.initials: R
authors.lastname: Huerbin
authors.forename: Michael A
authors.initials: MA
authors.lastname: Mathier
authors.forename: You-Tang
authors.initials: YT
authors.lastname: Shen
authors.forename: Richard P
authors.initials: RP
authors.lastname: Shannon
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D002395:Catecholamines / Q000008:administration & dosage / Q000494:pharmacology*; D003326:Coronary Circulation / Q000187:drug effects*; D004195:Disease Models, Animal; D004280:Dobutamine / Q000008:administration & dosage; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008955:Models, Cardiovascular; D009200:Myocardial Contraction / Q000187:drug effects*; D009638:Norepinephrine / Q000008:administration & dosage; D010101:Oxygen Consumption / Q000187:drug effects*; D012720:Severity of Illness Index; D013318:Stroke Volume / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D002395:Catecholamines; D004280:Dobutamine; D009638:Norepinephrine